Olema Pharmaceuticals, Inc. (OLMA) Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Olema Pharmaceuticals, Inc. NASDAQ:OLMA Healthcare · Biotechnology
Mkt Cap $612.48M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology granted inducement stock options to six new employees covering an aggregate 235,950 shares, effective October 1, 2026.
The grants were made under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with a 10-year term and $8.27 exercise price matching the last Nasdaq sale price.
This is a routine equity-compensation disclosure with no bearing on Olema's clinical pipeline, including the Phase 3 palazestrant program.
• 0mo ago AI analysis › Press Release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology granted newly appointed CFO Jason V. O'Byrne an employment inducement award of stock options to purchase 650,000 shares at an exercise price of $10.56 per share, matching the stock's September 1, 2026 closing price.
The Compensation Committee approved the grant under the 2022 Inducement Plan, with disclosure made per Nasdaq Listing Rule 5635(c)(4); it connects to O'Byrne's CFO appointment effective August 11, 2026.
Vesting runs four years, with a 25% cliff on August 11, 2027 and the remainder in 36 monthly installments — standard compensation mechanics with no bearing on the pipeline, led by palazestrant (OP-1250) in two Phase 3 trials and OP-3136 in Phase 1.
• 1mo ago AI analysis › Press Release
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology announced it will participate in three upcoming investor conferences in September 2026, including events hosted by Citi, Morgan Stanley, and H.C. Wainwright.
Management is scheduled to conduct fireside chats at each conference, with webcasts available on the company's investor relations website.
The release contains no new clinical or financial data, serving solely as a logistical update for investors.
• 2mo ago AI analysis › Press Release
Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer
Olema Oncology appointed Jason O’Byrne as Chief Financial Officer, bringing over two decades of experience in biotech finance and capital markets.
Mr. O’Byrne joins from Vir Biotechnology and previously served as CFO of Caribou Biosciences, where he led financial initiatives including an IPO.
The appointment comes as Olema approaches pivotal data from the OPERA-01 trial and prepares for a potential commercial launch of palazestrant.
• 2mo ago AI analysis › Press Release ● Major
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
Olema Oncology reported second quarter 2026 financial results with a net loss of $63.2 million, or $(0.61) per share, compared to a loss of $43.8 million in the prior year. The company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities, providing a strong balance sheet to fund operations into 2027.
Operationally, the company completed enrollment in the pivotal Phase 3 OPERA-01 trial evaluating palazestrant monotherapy in advanced breast cancer. Top-line data from this study are now expected in the first quarter of 2027, and initial Phase 1 data for the KAT6 inhibitor OP-3136 were presented at ASCO.
Olema announced a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with darolutamide for prostate cancer. The company also advanced enrollment in the Phase 3 OPERA-02 trial and is ramping preparations for a potential commercial launch.
• 2mo ago AI analysis › Press Release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology granted inducement stock options to seven new employees to purchase an aggregate of 254,540 shares of common stock.
The options have an exercise price of $11.28 per share, matching the closing price on August 3, 2026, and vest over four years with a 10-year term.
These awards were approved by the Compensation Committee under the Company's 2022 Inducement Plan in accordance with Nasdaq rules.
• 2mo ago AI analysis › Press Release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology granted stock options to eight new employees to purchase 215,800 shares of common stock.
The awards were made under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), effective July 1, 2026.
The exercise price of $12.08 per share equals the last reported sale price on the grant date, with options vesting over four years.
• 4mo ago AI analysis › Press Release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology granted stock options to six new employees to purchase 176,150 shares of common stock.
The awards were made under the 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with an exercise price of $12.71 per share.
The exercise price equals the last reported sale price on June 1, 2026, and the options vest over four years with a 10-year term.
• 4mo ago AI analysis › Press Release
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Olema Oncology announced a clinical trial collaboration and supply agreement with Bayer to evaluate its KAT6 inhibitor OP-3136 in combination with Bayer’s NUBEQA (darolutamide).
The Phase 1b/2 study will assess safety and preliminary anti-tumor activity in approximately 36 patients with metastatic castration-resistant prostate cancer (mCRPC), with initiation expected in the second half of 2026.
This marks the first clinical collaboration for OP-3136, expanding its development beyond breast cancer. Olema will lead the study and retain full global commercial rights to OP-3136, while clinical data and inventions will be jointly owned.
• 5mo ago AI analysis › Press Release
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Olema Oncology reported encouraging Phase 1 data for OP-3136, a novel KAT6 inhibitor, at the ASCO Annual Meeting.
The drug showed a manageable safety profile with no dose-limiting toxicities up to 45 mg and no discontinuations due to adverse events.
Among 19 evaluable patients, 13 experienced tumor shrinkage, including two confirmed partial responses, with evidence of on-target KAT6 inhibition.
• 5mo ago AI analysis › Press Release
Olema Oncology to Participate in Upcoming Investor Conferences
globenewswire.com • 5mo ago Press Release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology granted stock options to five new employees to purchase an aggregate of 154,700 shares of common stock, effective May 1, 2026.
The options were approved by the Compensation Committee under the Company's 2022 Inducement Plan with an exercise price of $14.32 per share, equal to the closing price on the grant date.
The awards vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments through the fourth year.
• 5mo ago AI analysis › Press Release
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
Olema Oncology appointed Prakash Raman, Ph.D., to its Board of Directors, adding two decades of biopharmaceutical executive leadership experience.
Dr. Raman currently serves as CEO of InduPro Therapeutics and previously led Ribon Therapeutics and held senior business development roles at Flagship Pioneering and Novartis.
The appointment comes as Olema advances palazestrant through two Phase 3 trials with pivotal OPERA-01 data expected this fall.
• 6mo ago AI analysis › Press Release
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
Olema Oncology announced it will present initial clinical data for OP-3136 from a Phase 1 study at the upcoming ASCO Annual Meeting in Chicago.
The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 trial, which is evaluating palazestrant plus ribociclib as a first-line treatment for advanced breast cancer.
OP-3136 is a novel oral selective KAT6A/B inhibitor currently being studied as monotherapy and in combination with endocrine therapy.
• 6mo ago AI analysis › Press Release
Olema Oncology to Participate in Upcoming Investor Conferences
globenewswire.com • 8mo ago Press Release ● Major
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 8mo ago Press Release
Olema Oncology Announces Departure of Chief Operating and Financial Officer
globenewswire.com • 9mo ago Press Release ● Major
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • 9mo ago Press Release
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com • 9mo ago 
